← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
darunavir and cobicistat
J05AR14
Forms & Strengths
- darunavir 800mg and cobicistat 150mg tablets
- darunavir 600mg and cobicistat 100mg tablets (for co-administration with other medicines)
- oral administration
Adult Dosing
- 1 tablet of darunavir 800mg and cobicistat 150mg orally once daily
- in treatment-naive or treatment-experienced patients, dose may be adjusted based on co-administered drugs
- dosage adjustment required for renal impairment
Pediatric Dosing
- not recommended for pediatric patients below 18 years of age due to lack of data
- use in pediatric patients should be based on a comprehensive benefit-risk assessment
Indications
- treatment of HIV-1 infection in adult patients
- use in combination with other antiretroviral agents
Mechanism of Action
- darunavir: HIV protease inhibitor, blocks proteolytic cleavage of viral protein precursors
- cobicistat: cytochrome P450 3A inhibitor, increases systemic exposure of darunavir
Contraindications
- hypersensitivity to darunavir or cobicistat
- co-administration with certain drugs (e.g., alfuzosin, amiodarone, quetiapine, rifampicin)
- liver disease (Child-Pugh class C)
Adverse Reactions
- diarrhea
- abdominal pain
- rash
- lipodystrophy
- liver enzyme elevations
- myocardial infarction (increased risk)
Drug Interactions
- increased risk of adverse reactions with certain antiarrhythmics, antihistamines, and ergot derivatives
- reduced efficacy with certain anticonvulsants, antibiotics, and antifungals
- increased levels of certain statins, benzodiazepines, and immunosuppressants
Curated Content: Needs Vetting Before Put to Clinical Use